lipase
lipase: sourced relationships with 1 company · 3 clinical trials tracked · 1 FDA decision.
lipase evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could lipase → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| AbbVie Inc. (ABBV) Reported 2009-04-30 · Current development: unknownSource Fibrosing Colonopathy | — |
Clinical Trial Registry Records (3)
A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC
Primary endpoint: Primary Objectives: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)
Primary endpoint: Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving ZENPEP
Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis
Primary endpoint: transfer of dietary nitrogen to metabolic pools
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with lipase?
lipase has dated SEC/FDA relationship records for AbbVie Inc..
How many clinical trials involve lipase?
BioSniper tracks 3 clinical trials involving lipase.
What is lipase's latest FDA decision?
The most recent tracked FDA decision for lipase is Approval for 1 INDICATIONS AND USAGE CREON ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. CREON is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients., dated April 30, 2009.